Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04606381
Title A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

hepatocellular carcinoma

breast cancer

malignant mesothelioma

colorectal cancer

ovarian cancer

Advanced Solid Tumor

lung non-small cell carcinoma

gastroesophageal cancer

thyroid gland medullary carcinoma

head and neck squamous cell carcinoma

renal cell carcinoma

Therapies

Amivantamab-vmjw + Lazertinib

Amivantamab-vmjw + Lazertinib + rHuPH20

Amivantamab-vmjw

Amivantamab-vmjw + rHuPH20

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.